Literature DB >> 11074369

Adeno-associated virus vectors for gene therapy: more pros than cons?

P E Monahan1, R J Samulski.   

Abstract

Gene therapy vectors based on the adeno-associated virus (AAV) are being developed for a widening variety of therapeutic applications. Enthusiasm for AAV is due, not only to the relative safety of these vectors, but also to advances in understanding of the unique biology of this virus. This review examines a number of long-standing concerns regarding the utility of AAV for gene transfer in light of many new insights into the biology, immunology and production of AAV.

Entities:  

Mesh：

Year:  2000        PMID： 11074369     DOI： 10.1016/s1357-4310(00)01810-4

Source DB:  PubMed          Journal:  Mol Med Today        ISSN： 1357-4310


  48 in total

1.  Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Authors:  Bruce C Schnepp; K Reed Clark; Dori L Klemanski; Christina A Pacak; Philip R Johnson
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 2.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease.

Authors:  Maria Pilar Bayona-Bafaluy; Bas Blits; Brendan J Battersby; Eric A Shoubridge; Carlos T Moraes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-22       Impact factor: 11.205

Review 4.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

Review 5.  Cardiac gene therapy.

Authors:  Antoine H Chaanine; Jill Kalman; Roger J Hajjar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

Review 6.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

Review 7.  Gene therapy for Fabry disease.

Authors:  C Siatskas; J A Medin
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

8.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 9.  Tools for resolving functional activity and connectivity within intact neural circuits.

Authors:  Joshua H Jennings; Garret D Stuber
Journal:  Curr Biol       Date:  2014-01-06       Impact factor: 10.834

10.  Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.

Authors:  Anne D Lewis; Ruju Chen; David C Montefiori; Philip R Johnson; K Reed Clark
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.